Reczek Neurology And Neuro-Oncology is categorized under Oncologists in Concord, MA and active since 2010.
Reczek Neurology And Neuro-Oncology was established in 2010, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Oncologists business, which does work in the B2C market, and is classified as a Oncologists, under code number 621111 by the NAICS.
If you are seeking more information, feel free to contact Jeanine Reczek at the company’s single location by writing to 54 Baker Avenue Extension # 100, Concord, Massachusetts MA 01742 or by phoning (978) 369-0030. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Reczek Neurology And Neuro-Oncology |
Contact Person: | Jeanine Reczek |
Address: | 54 Baker Avenue Extension # 100, Concord, Massachusetts 01742 |
Phone Number: | (978) 369-0030 |
Annual Revenue (USD): | $100.000 to $499.999 |
Founded: | 2010 |
Location Type: | Single Location |
Employee Number: | 1 to 4 |
Business Type: | B2C (Business to Consumer) |
Business Category: | Oncologists |
SIC Code: | 8011 |
NAICS Code: | 621111 |
Share This Business: |
Reczek Neurology And Neuro-Oncology was started in 2010 to provide professional Oncologists under the SIC code 8011 and NAICS code 621111. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Jeanine Reczek for inquiries that concern Reczek Neurology And Neuro-Oncology by calling the company number (978) 369-0030, as your correspondence is most welcome. Additionally, the physical location of the single location of Reczek Neurology And Neuro-Oncology can be found at the coordinates 42.460302,-71.386126 as well as the street address 54 Baker Avenue Extension # 100 in Concord, Massachusetts 01742.
For its online presence, you may visit Reczek Neurology And Neuro-Oncology’s website at and engage with its social media outlets through on Twitter and on Facebook.